Last reviewed · How we verify
Neoadjuvant chemoradiotherapy based on irinotecan
At a glance
| Generic name | Neoadjuvant chemoradiotherapy based on irinotecan |
|---|---|
| Sponsor | Zhejiang Cancer Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial (PHASE2)
- Folfox+Irinotecan+Chemort In Esophageal Cancer (PHASE2)
- Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer (PHASE2)
- Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer (PHASE2)
- A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer (PHASE2)
- UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer (PHASE4)
- A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC (PHASE2)
- Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: